Showing posts with label Bone Marrow Transplant. Show all posts
Showing posts with label Bone Marrow Transplant. Show all posts

Thursday, February 23, 2017

RABBITS could be the secret weapon in the fight against bone marrow cancer

A virus found only in rabbits was found to eradicate an aggressive blood cancer

In a study on mice, 25% had no signs of the disease after being given the virus

Experts say the MYVX virus strengthens the immune system and fights tumors




A virus found only in rabbits can eradicate an aggressive form of bone marrow cancer in mice

Multiple myeloma (MM), which is difficult to treat, is the second most common form of blood cancer.

Currently, patients are given stem cell transplants to try and overcome the disease.

But many relapse, making it more deadly, as the innovative treatment often fails to remove all of the cancerous cells.

However, using myxoma virus (MYXV) - which is only found in rabbits - during this process was successful in eradicating MM cells.

This prevented the relapse of the disease, the researchers from the Medical University of South Carolina and University of Oslo, Norway found.

They also assessed whether using MYXV could have a benefit on the disease outside of the stem cell transplant.

JUMP for More





Tuesday, December 1, 2015

Here's how 'bone marrow transplants' work

Ask the Expert: The type of cancer, patient's age, general health, availability of donors and other factors determine the type of transplant

Question: 

Is one person’s bone marrow literally transplanted into another during a bone marrow transplant?

Answer:  

Hematopoietic stem cell transplants (commonly referred to as bone marrow transplants) are typically used to treat blood cancers such as leukemia, lymphoma and multiple myeloma.

Hematopoietic stem cell transplant encompasses peripheral blood stem cell transplant, bone marrow transplant and alternative donor transplant as well. In the majority of cases, the source of the stem cell to complete the transplant is taken from the bloodstream of the patient or a donor (peripheral blood stem cell transplant).

In a smaller number of cases, the patient may receive stem cells from umbilical cord blood or stem cells from a donor’s actual bone marrow.

If the stem cells are taken from the patient, it is called an autologous transplant. If the stem cells are from a donor, it is an allogeneic transplant. Both types of transplants use hematopoietic stem cells that can have the capacity for self-renewal and the ability to form all types of blood cells including red blood cells, white blood cells and platelets.

The stem cells are transfused into the patient’s bloodstream, where they migrate to the bone marrow and grow into healthy new blood cells and therefore repopulate the bone marrow.

In autologous transplants, the dose of chemotherapy is what provides the benefit of disease control/cure. It is more commonly considered as a therapeutic modality for multiple myeloma, where it offers disease control and for recurrent Non-Hodgkin Lymphoma or Hodgkin’s disease where it has the potential for cure.

In allogeneic transplants, the dose of chemotherapy provide benefit but also the interaction between the donor and recipient cells allow a protective response called graft versus tumor effect. It should be noted that each type of transplant is associated with its own risks and benefits.

If an allogeneic transplant is to be performed, a donor search is initiated. Donors have to be closely genetically matched. The donor search usually begins with full blood siblings, who have about a 25 percent chance of being a match (matched-related donor).

For those individuals without a sibling match (70 percent of patients) the search is entered into a registry of donors through the National Marrow Donor Program, where a potential donor is identified (matched-unrelated donor). For those without a full match alternative donor transplants such as umbilical cord or haploidentical transplants (parent or children) may be considered.

The patient’s type of cancer, age, general health, availability of donors, and other factors determine whether an autologous or allogeneic transplant is performed.

The Cancer Transplant Institute at the Virginia G. Piper Cancer Center at HonorHealth has been recognized by the NMDP. It is also one of only 106 U.S. bone marrow transplant centers accredited by the Foundation for the Accreditation of Cellular Therapy for both autologous and allogeneic transplants.


Veena Fauble, MD, is a physician at the Cancer Transplant Institute at the Virginia G. Piper Cancer Center at HonorHealth. For more information about bone marrow transplants available at HonorHealth, please contact an oncology nurse navigator at 480-323-1339 or HonorHealth/cancer.

LINK

Thursday, October 8, 2015

Playing it Safe: Avoiding Infections After Stem Cell Transplants

After stem cell transplants for blood cancers, patients — with help from their caregivers — must be careful to avoid infections.

Nikki Mann knows first-hand that it takes patience, diligence and teamwork to help a loved one recover from a stem-cell transplant following a blood cancer diagnosis.

Her husband, Bill Mann, successfully underwent a stem-cell transplant in 2004, four years after he was diagnosed with multiple myeloma at the age of 45.

Although the transplant was uncharted territory for the Manns, Nikki’s role as caregiver had already been cemented through their initial years of his cancer saga. This time, they both had to be mindful of the heightened risk for infection in the ensuing days and weeks, because a stem-cell recipient’s immune system is weakened for a period of time after a transplant.


From an infection standpoint, the main risks are viral and fungal infections, but some bacterial infection risk is present too, particularly for patients whose treatment regimen relies on intravenous catheters that stay implanted for months at a time, says medical oncologist Ravi Vij, a specialist in bone marrow/stem cell transplants at the Siteman Cancer Center at the Washington University School of Medicine in St. Louis, Mo.

Jump for some GREAT tips

Thursday, February 12, 2015

Stem cell transplants may work better than existing drug for severe multiple sclerosis

Stem cell transplants may be more effective than the drug mitoxantrone for people with severe cases of multiple sclerosis (MS), according to a new study published in the February 11, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

The study involved 21 people whose disability due to MS had increased during the previous year even though they were taking conventional medications (also known as first-line treatments). The participants, who were an average age of 36, were at an average disability level where a cane or crutch was needed to walk.
In MS, the body's immune system attacks its own central nervous system. In this phase II study, all of the participants received medications to suppress immune system activity. Then 12 of the participants received the MS drug mitoxantrone, which reduces immune system activity. For the other nine participants, stem cells were harvested from their bone marrow. After the immune system was suppressed, the stem cells were reintroduced through a vein. Over time, the cells migrate to the bone marrow and produce new cells that become immune cells. The participants were followed for up to four years.

"This process appears to reset the immune system," said study author Giovanni Mancardi, MD, of the University of Genova in Italy. "With these results, we can speculate that stem cell treatment may profoundly affect the course of the disease."

Intense immunosupression followed by stem cell treatment reduced disease activity significantly more than the mitoxantrone treatment. Those who received the stem cell transplants had 80 percent fewer new areas of brain damage called T2 lesions than those who received mitoxantrone, with an average of 2.5 new T2 lesions for those receiving stem cells compared to eight new T2 lesions for those receiving mitoxantrone.

For another type of lesion associated with MS, called gadolinium-enhancing lesions, none of the people who received the stem cell treatment had a new lesion during the study, while 56 percent of those taking mitoxantrone had at least one new lesion.

Mancardi noted that the serious side effects that occurred with the stem cell treatment were expected and resolved without permanent consequences.
"More research is needed with larger numbers of patients who are randomized to receive either the stem cell transplant or an approved therapy, but it's very exciting to see that this treatment may be so superior to a current treatment for people with severe MS that is not responding well to standard treatments," Mancardi said.

Jump for More Links

Thursday, December 18, 2014

Stem cell transplant can be outpatient treatment for some

Before I cut and paste this story, I must give my own views on this.  I'm not convinced that this is safe for the patient.

Although Dom's transplant was over 5 years ago, it was SO MUCH DIFFERENT.... for the better, I believe.

Firstly, after living in this home for 25 years, there was no way that I'd bring my husband home to 25 years of "stuff".

Instead, we moved into an apartment a few weeks prior to his procedure.  I hired a guy to come in and "sanitize" the apartment. (A fog and a spray).

After the transplant, he was in the hospital for several (?) weeks.  Once he returned to our new home, he was not permitted to eat ANY fresh vegetables or fruit.  Canned, only.... as long as the cans were washed with warm soapy water and opened up by hand.

It was a couple of months before she allowed him to go out for pizza and a movie..... the movies were matinees, and the meals would be during "off hours", so as to pretty much have the restaurant to ourselves.  (MASK)

His mother was in poor health in her mid-nineties.  NOPE.  Finally, our doctor allowed him to put on his mask, park in her driveway to allow her to visit her only child.

If we had to do it all over again, we'd choose the same method.  He's worth it.  *winking and smiling*
************************************************************
Bringing a major medical treatment home. Patients once spent weeks in the hospital. Now they can get a stem cell transplant and go home. It means tackling a lot of hurdles, but this new idea is offering tremendous relief to patients.

She passes the time with a little knitting … and a visit with her doctor. Then there’s a quick flush of the central line in her chest, placed this past summer before Rebecca Zoltoski began a four-month course of chemotherapy to fight myeloma – cancer of her bone marrow.

Rebecca Zoltoski, stem cell transplant patient: “You do what you have to do.”

But this is not a doctor’s appointment. This is day three of Rebecca’s stem cell transplant. Her doctors are ready to infuse a batch of new cells – her own – with the hope they will grow into healthy bone marrow.

Dr Michael Bishop, University of Chicago Medicine, medical oncologist: “Think of the stem cells as the seeds of the bone marrow. It takes time to start growing and maturing and appearing in the peripheral blood, and that’s about a 10-day process.”

As the cells grow, patients wait. It’s an intense process that typically requires a 21-day stay in the hospital. But Rebecca is an outpatient. And after her daily check in – she’s ready to head out.

Dr Michael Bishop: “We would take her and monitor her blood counts, monitor her kidney and liver functions and make sure she’s doing ok. If everything looks cool, we send her on her merry way with very strict instructions that in that interim, before we would see her the next day, if she developed signs of infection, fever, cough, diarrhea, that she immediately gives us a phone call.”

It’s a new program at University of Chicago Medicine – the outpatient stem cell unit has been up and running for about three weeks.

Rebecca Zoltoski: “This afternoon I hope to get out and get a good walk in so I can try to get some of my energy back because I find that helps me a lot. I wouldn’t really be able to be outside if I were here as an inpatient.”

Dr Michael Bishop: “Knowing you are going home every day, that’s the psychological advantage. They have the comfort of their own home, own bed, foods they are used to and like.”

Rebecca Zoltoski: “I did have some concerns about things that could happen, negative things that could happen.”

And there are risks. Patients undergoing a stem cell transplant have weak immune systems and extremely low blood counts – their ability to fight infection is severely compromised.

Dr Michael Bishop: “Most of the time, 75% of the time the patient is going to be fine. One in four will have to be admitted to the hospital primarily for signs and symptoms of an infection.”

That’s why doctors place constraints on outpatients.

Dr Bishop: “Limited to no crowds, wear a mask, strict hand washing.”

Still, the outpatient process appealed to Rebecca.


Rebecca Zoltoski: “I have an 11-year-old at home, and it’s nice to be able to see her. And it’s nice for her to be able to see me, and know I’m doing ok. That’s been the positive of it.”

http://wgntv.com/2014/12/17/stem-cell-transplant-can-be-outpatient-treatment-for-some/

Thursday, November 6, 2014

Early Relapse After SCT Important for Prognosis in Multiple Myeloma

Patients who experienced early relapse of their multiple myeloma after undergoing autologous stem cell transplantation had worse overall survival and progression-free survival compared with those patients with a longer time to relapse, according to the results of a study published in Bone Marrow Transplantation.

“We conclude that early relapse after autologous stem cell transplantation appears to be a major prognostic variable in multiple myeloma,” wrote researchers led by Victor H. Jimenez-Zepeda, MD, of Princess Margaret Cancer Centre, Toronto. “Patients with early relapse post-autologous stem cell transplantation should biologically be characterized in prospective studies to better understand the mechanisms of resistance associated with this particular entity.”

According to the study, prior research has identified several factors associated with worse outcomes in the post-transplant realm, including elevated plasma cell labeling index, more than one treatment regimen prior to transplant, failure to achieve a complete response, and loss of complete response within 1 year of transplant.

In this study, Jimenez-Zepeda and colleagues analyzed the effects of early relapse on survival. They evaluated 184 consecutive patients with multiple myeloma who underwent single autologous stem cell transplantation between January 2002 and September 2012 and had novel induction therapy.

Of these patients, 15.3% achieved a complete response and 57.1% achieved a very good partial response at day 100 post-transplant. A smaller percentage of patients with early relapse had a very good partial response or better compared with those without early relapse (38% vs 70%; P = .008) at day 100 post-transplant.

The median progression-free survival for the group analyzed was 25.4 months. The median time to relapse was 17.2 months. Early relapse occurred in 36% of the patients who relapsed and was most common in patients treated with thalidomide induction regimens. According to the researchers, this result suggests that “second-generation immunomodulatory drugs and proteasome inhibitors might be better options to prevent early relapse to occur in the setting of autologous stem cell transplantation.”

Patients with early relapse had a median overall survival of 20 months compared with 93 months for those without early relapse (P = .001). Even among patients with a very good partial response who experienced early relapse, overall survival was significantly shorter than those patients who achieved the same level of response but without early relapse (38.53 months vs 79.3 months; P = .013).

The researchers evaluated the prognostic value of cytogenetic features on outcomes, but found that only a single case in the 27 early relapses had high-risk cytogenetics.

Finally, the researchers examined outcomes adjusted for age, best response to induction therapy, best response at day 100 post-transplant, and other variables, and found that early relapse was a major independent prognostic factor for overall survival in these patients.

“As patients with early relapse exhibited a lower rate of very good partial response or higher, new-generation drugs and strategies such as consolidation or maintenance should be considered especially for those patients where there is a high tumor burden,” the researchers wrote. “Studies on minimal residual disease and a more broad and deep panel of cytogenetics will help identifying some intrinsic biological factors that could be associated with lack of response sustainability.”

- See more at: http://www.cancernetwork.com/multiple-myeloma/early-relapse-after-sct-important-prognosis-multiple-myeloma#sthash.RGo9BMEq.dpuf

Saturday, October 25, 2014

Mother Jones Magazine Blogger Diagnosed With Multiple Myeloma

This fellow might be interesting to follow as he continues his journey towards remission.

Friday Cancer Blogging - 24 October 2014
—By Kevin Drum

A few of you have probably cottoned onto the fact that people don't usually spend a week in the hospital for a broken bone, even a backbone. So in the long tradition of releasing bad news on Friday afternoon, here's my first-ever Friday news dump.

When I checked in to the hospital Saturday morning, the first thing they did was take a bunch of X-rays followed by a CT scan. These revealed not just a fractured L3, but a spine and pelvis dotted with lytic lesions that had badly degraded my bones. That's why a mere cough was enough to send me to the ER. It was just the straw that broke an already-weakened camel's back. Later tests showed that I also had lesions in my upper arm, my rib cage, and my skull—which means that my conservative friends are now correct when they call me soft-headed.

The obvious cause of widespread lytic lesions is multiple myeloma, a cancer of blood plasma cells, and further tests have confirmed this. (The painful bedside procedure on Tuesday was a bone marrow biopsy. Bone marrow is where the cancerous plasma cells accumulate.)

I know from experience that a lot of people, especially those who have been through this or know a family member who's been through this, will want to know all the details about the treatment I'm getting. I'll put that below the fold for those who are interested. For the rest of you, here's the short version: I'm young, I'm not displaying either anemia or kidney problems, and treatments have improved a lot over the past decade. So my short-term prognosis is pretty positive. Treatment involves two to three months of fairly mild chemotherapy, which has already started, followed by a bone marrow transplant. My oncologist thinks I have a very good chance of complete remission.

The longer-term prognosis is less positive, and depends a lot on how treatments improve over the next few years. But I figure there's not too much point in worrying about that right now. Better to stay focused on the current regimen and see how I respond to that. Wish me well.

OK, here are all the gruesome details of my treatment regimen. Yesterday I had a kyphoplasty, which we hope will repair my fractured lumbar bone and relieve my immediate pain. Once a month I'll be getting an IV infusion of Aredia, a bone-strengthening medication.

Because I'm young and my symptoms are mostly limited to the bone lesions, I'm a good candidate for a bone marrow transfusion. For that reason, my oncologist has recommended treatment with three drugs:

Decadron, a corticosteroid
Velcade
Cytoxan

I've already begun the Decadron treatment, and I'll start the other two later today. The total treatment cycle is 2-3 months. It's supposed to be a fairly mild regimen with not too many hideous side effects. We'll see. As usual, the drugs put me at higher risk of infection, so I'll be taking Acyclovir as a prophylactic antiviral.

Assuming this all goes well, it will be followed by a bone marrow transfusion. Basically, they suck the blood out of my body, filter it, and pump it back in. There's more to it than that, of course, but we'll take these things one step at a time.

That's basically it. Obviously there will be loads of ongoing tests and imagery to see how things are going, and I'll continue to have to watch carefully for signs of relapse for the rest of my life. For the time being, though, I'm alive and my prospects for staying that way seem pretty good.

Kevin's Blog Link

Friday, October 3, 2014

Long-Term Isolation Poses Special Challenges after Stem Cell Transplantation

“The thing I remember most about the weeks after the transplant was that everyone who came in to see me was wearing a mask. I didn’t have to wear one, but they did. Day after day, week after week, all I saw of the people I loved was the little rectangle of their faces — eyes and forehead — that the mask did not cover. Everyone who touched me was wearing gloves, and I grew to miss that, too, the feel of holding (my partner’s) hand, the touch of my sisters’ and friends’ lips on my cheek.”

In this quote from her 2014 memoir, Everybody’s Got Something, morning news show veteran Robin Roberts crystallized the sense of disconnection ubiquitous among stem cell and bone marrow transplant, or BMT, patients. Ms. Roberts — who anchors ABC’s Good Morning America — received a stem cell transplant at Memorial Sloan Kettering in the fall of 2012 to treat the life-threatening bone marrow disorder myelodysplastic syndrome (MDS).

For the hundreds of adults who undergo stem cell or bone marrow transplants each year at MSK, mostly for blood cancers, Ms. Roberts’ book relates a familiar experience. Beyond the physical difficulties of the treatment itself, this type of transplantation requires prolonged isolation from everyday life, adding emotional challenges to an already steep recovery.

“With any diagnosis that threatens your life, even for patients with the greatest amount of support, there may be a sense of aloneness at different points in the illness and treatment experience,” says MSK social worker Margery Davis, who works with patients on the Adult Bone Marrow Transplant Service. “For transplant patients, there’s also a physical isolation and restrictive lifestyle imposed by the treatment that’s very different from other experiences.”

Creating Comfort during the Hospital Stay

During hospitalization, which frequently ranges from two to six weeks, it’s paramount to keep bacteria, viruses, and fungi from infecting BMT patients — particularly for those receiving a donor-derived, or allogeneic, transplant, whose immune systems are being entirely rebuilt as these “foreign” cells engraft in their bone marrow. That’s why all visitors, along with medical staff, bear the rectangular visage of masks and don gloves, as Ms. Roberts poignantly describes. It’s only after patients’ blood counts begin to rise again that they’re even allowed out of their hospital room to walk the halls.

This isolation doesn’t have to equal solitary confinement, since a small circle of family and friends can spend time with BMT patients both in the hospital and at home in the first months after discharge. Instead, the separation stems from being deprived of normal sights, sounds, smells, tastes, and touches along with regular patterns of socializing, working, shopping, and moving about.

“People generally feel well taken care of here, so I wouldn’t say the isolation is only because of the environment and the masks and gloves,” Ms. Davis says. “I think the room isolation contributes to feeling disconnected at times. It’s hard to cope being in a room that represents their illness and treatment 24-7.”


To compensate, some patients outfit their space for the long haul with homey touches such as comforters, photographs, and simple wall hangings, says Ann Jakubowski, a physician on MSK’s Adult Bone Marrow Transplantation Outpatient Unit. They can also shun hospital gowns and wear their own leisure clothes during much of their stay.

Making Adjustments at Home

Psychologically, a far more vulnerable time for most BMT patients is the 100 or so days after they leave the hospital, according to Dr. Jakubowski and Ms. Davis. At home, a multitude of adjustments await, all to minimize germs: Dirt and dust are enemies. Many foods are discouraged. No taking mass transit, no eating out, no venturing into crowds. Visitors must be limited and screened to make sure they’re not sick. Even the family pet — because it may carry bacteria or other infectious organisms — might have to temporarily live elsewhere.

“For some people, their dog is like their baby, especially for those who don’t have kids,” Dr. Jakubowski says. “It’s really hard on them. There are a lot of rules and recommendations they are given while their immune system is suppressed…all trying to protect them.”

Unless they’re able to work from home, many patients must also leave their jobs for at least three months, which can add to the mounting financial strain of treatment. Some people also experience the long separation from work as a blow to their identity. Creating structure around these home-based months — when patients are encouraged to limit outside activities to only frequent follow-up medical visits — is key. Quiet routines that include bathing, exercise, reading, and light household chores such as folding laundry can help focus patients during seemingly endless days.

“I think the slow recovery is very hard for people to sit with,” Ms. Davis says. “People need to get back to work for financial reasons, but also for purpose and meaning in their life. They need to create a structure for themselves without being able to work.”

Strategies for Recovery

To smooth recovery psychologically and physically during isolation, Dr. Jakubowski and Ms. Davis offer the following advice. These tips may be helpful not only to patients who have undergone BMTs but also to those whose immune systems may be compromised due to chemotherapy or other cancer treatments.

Keep active.

Yes, your energy is limited, and you can’t hit the gym. But while you’re hospitalized, get out of bed at least twice a day, if possible, and do the exercises hospital staff members recommend, which reduce the risk of infection and help maintain muscle tone. At home, short treks outside (away from crowds) help build endurance, and wisely selected video fitness games such as tennis, basketball, or bowling offer a surprisingly effective workout. “It’s about keeping a positive perspective and moving forward as opposed to being in a sick mode,” Dr. Jakubowski says.

Stay connected.

Virtual connections — through email, Skype, and social media outlets such as Facebook — can fill the void while face-to-face contact is scarce. MSK offers the online community Connections for patients and caregivers to give and receive support. Just be careful about chat rooms and websites operating without oversight from a major health organization, Dr. Jakubowski says, since information may be misleading or wrong.

“With the Internet, it’s easier to keep some connection with other people,” she says. “You can see and hear them in ways that wouldn’t have been possible ten or 15 years ago. And in terms of being able to talk to your kids while you’re in the hospital, or talk to your friends, being able to use Skype is huge.”

Take a taste.

The chemotherapy and radiation typical before stem cell transplantation, as well as some of the medications needed to protect the transplant patient, temporarily affect many patients’ sense of smell and taste, lowering appetite and causing varying degrees of weight loss. Despite your aversion, “keep trying tastes of everything — salty, sweet, and different textures — to see what works right now,” Dr. Jakubowski suggests.

Focus on the end game.

Set small, short-term goals such as attending a social event (with your doctor’s blessing) so you have something to look forward to. “It’s a relief to go even to the grocery store,” Ms. Davis says. “It’s a sign you’re moving toward recovery, toward normal life.”

But don’t do too much, too soon, even if you’re feeling stronger, Dr. Jakubowski warns. “Some patients live by the rules…and others feel very cheated that things aren’t normal. It’s maybe a year of your life, but if it’s what it takes to save your life, try to hang in there.”

Set expectations.

Appoint a “spokesperson” who can keep others in the loop about your transplant and recovery. This person can also help set expectations for your at-home healing period. “Patients say that everyone expects them to do everything they did before, but just because you’re home doesn’t mean you’re back to normal,” Ms. Davis says. “It’s a very high-risk phase, and I think a sense of isolation comes when people have a different schedule for you to get back to normal than the real schedule.”

LINK

Monday, April 28, 2014

Bone Marrow Transplants A Lot Safer Now

Sandra Haber, a 65-year-old psychologist in Brooklyn, wants everyone to know how easy it is now to donate bone marrow.

Hers was failing. She was anemic, bled easily and had little resistance to infection. As her condition progressed toward leukemia, doctors at Memorial Sloan-Kettering Cancer Center urged her to get a bone-marrow transplant. Fortunately, there was a donor: Testing showed that a sister living in New Mexico was a perfect match.

But at first Haber's sister was hesitant, fearful of the general anesthesia, painful withdrawal of marrow from a hip bone and difficult recovery she thought was involved. Yet she came to New York for further tests and learned that the process was simple and safe: basically a lengthy blood donation after a week of daily injections to spur her own bone marrow to produce an oversupply of stem cells.

About 90 percent of bone marrow "transplants" are now done this way, most often with stem cells from a matched donor's blood, sometimes from a baby's umbilical cord and placenta or the patient's own stem cells. After the recipient's own dysfunctional marrow is destroyed by intensive chemotherapy and sometimes total body radiation, the donated stem cells are infused into the recipient's blood through a special intravenous line, called a central line. The cells find their way to bone marrow, where they gradually restore the recipient's ability to produce red and white blood cells and platelets.

"A stem cell transplant is not a walk in the park," Haber said. "It's more like a marathon than a sprint, and the healing process is long and not linear."

It typically takes six months to a year to regain full blood cell production and immune function, during which special precautions are essential.

But when a life is saved, the challenges are worth it, recipients say. Haber said her weeks in the hospital in relative isolation were not especially difficult. She described the fatigue afterward as more of a hardship, but that, too, abated as she has gradually regained her former energy.

Now Haber wonders why a sign in her hospital still reads "Bone Marrow Transplant Unit," when marrow donation is a rarity and the thought of it may scare off potential donors.

Many in need of healthy bone marrow die before a good match can be found. Haber thinks if the language changed, far more people from diverse ethnic and racial groups might be willing to join the American Bone Marrow Donor Registry -- whose name perhaps should also be changed.

Donors must be 18 to 60 and healthy. Registration involves just a cheek swab from which the donor's tissue type is analyzed and stored in a national database.

When someone who needs new bone marrow has no close match among eligible relatives, doctors check the registry for a matching volunteer elsewhere. The need is especially great for patients who are African-American, Asian or of mixed ethnic or racial backgrounds.

A match is determined by checking proteins called HLA antigens present on cells from the donor and recipient. As with other traits, people inherit the genes that determine these antigens from each parent; the more genetically distant the parents, the less common the mix of antigens is likely to be. Without a very close match, the donor's cells are likely to attack the recipient's tissues, a potentially fatal complication called graft-versus-host disease.

Stem cell transplants can help people whose bone marrow is diseased or dysfunctional and unable to produce the red blood cells that carry oxygen, white blood cells that fight infections, or platelets that enable the blood to clot. Such conditions include cancers like leukemia, certain lymphomas, multiple myeloma and aplastic anemia; inherited disorders like sickle cell anemia and thalassemia; and severe immune deficiency disorders in newborns.

For cancer patients, a stem cell transplant offers an additional benefit: The new blood cells can attack errant cancer cells that may have survived the original chemotherapy.

Stem cell transplants are expensive, $100,000 to $200,000.

Prospective patients are urged to check with their insurance carriers before embarking on the process.

LINK

Thursday, March 20, 2014

20 years later, donor and recipient repeat stem cell transplant

This is a real "FEEL GOOD STORY"!!!

DALLAS — Though he feels a little weary, Drew Harrison has a strong story of survival.

“That was probably the hardest thing in the world — to convince me that I was relapsed,” Harrison said.

A bone marrow transplant in 1994 saved Harrison’s life. But the Dallas resident hadn’t counted on needing it saved a second time.

“At one point in time, I had almost given up. She and my other daughters kept trying to convince me that even though I’m older, that I had years left,” he said.
"She" is Michele Tanner of Longview, the donor the first time around. When Tanner heard Harrison needed her again, 20 years later, she had an immediate answer.

“I told him whatever we needed to do, we’d get it done,” Tanner said.
And that’s what they did Wednesday, with drip after drip of the life-saving stem cells from Tanner’s bone marrow feeding into Harrison’s arm.

When Tanner first donated her marrow to Harrison, the procedure required a long hospital stay. Today, it’s done on an outpatient basis.

It’s the only cure, according to Harrison’s doctor, who was involved in both transplants.

“[It's] unusual after all that time doing well [to need another transplant], but sometimes it happens,” said Dr. Luis Pineiro from Baylor Medical Center, where both transplants were performed.

It’s not likely, but if it ever happened again?

Michele Tanner seems the type who’d gladly walk with Harrison down that road again.

LINK

Friday, October 25, 2013

Types of stem cell transplants for treating cancer

In a typical stem cell transplant very high doses of chemo are used, often along with radiation therapy, to try to destroy all of the cancer. This treatment also kills the stem cells in the bone marrow. Soon after treatment, stem cells are given to replace those that were destroyed. These stem cells are given into a vein, much like a blood transfusion. Over time they settle in the bone marrow and begin to grow and make healthy blood cells. This process is called engraftment.

There are 3 basic types of transplants. They are named based on where the stem cells come from.

Autologous (aw-tahl-uh-gus)—the cells come from you

Allogeneic (al-o-jen-NEE-ick or al-o-jen-NAY-ick)—the cells come from a matched related or unrelated donor

Syngeneic (sin-jen-NEE-ick or sin-jen-NAY-ick)—the cells come from your identical twin or triplet
***********************************************************************
Autologous stem cell transplant

In this type of transplant, your stem cells are taken before you get cancer treatment that destroys them. Your stem cells are removed, or harvested, from either your bone marrow or your blood and then frozen. After you get high doses of chemo and/or radiation the stem cells are thawed and given back to you.

One advantage of autologous stem cell transplant is that you are getting your own cells back. This means there is no risk that your immune system will reject the transplant or that the transplanted cells will attack or reject your body.

A possible disadvantage is that cancer cells may be harvested along with the stem cells and then put back into your body. To prevent this, doctors may give you anti-cancer drugs or treat your stem cells with other methods to reduce the number of cancer cells that may be present. (See the section, “Getting rid of cancer cells in autologous transplants.”) Another disadvantage is that you have the same immune system when your stem cells engraft. The cancer cells were able to grow in the presence of your immune cells before, and may be able to do so again.

This kind of transplant is mainly used to treat leukemias, lymphomas, and multiple myeloma. It’s sometimes used for other cancers, like testicular cancer and neuroblastoma, and certain cancers in children. Doctors are looking at how autologous transplants might be used to treat other diseases, too, like systemic sclerosis, multiple sclerosis, Crohn disease, and systemic lupus erythematosis.

Tandem transplants

A tandem transplant is also called a double autologous transplant. In a tandem transplant, the patient gets 2 courses of high-dose chemo, each followed by a transplant of their own stem cells. All of the stem cells needed are collected before the first high-dose chemo treatment, and half of them are used for each transplant. Most often both courses of chemo are given within 6 months, with the second one given after the patient recovers from the first one.

Tandem transplants are sometimes used to treat certain types of cancer, but doctors do not agree on when and how to use this type of transplant. For many people, the risk of serious outcomes is quite high. Tandem transplants are still being studied to find out when they might be best used.

Allogeneic stem cell transplant

In this type of transplant, the stem cells do not come from the patient, but from a donor whose tissue type closely matches the patient. (This is discussed later under “HLA matching” in the section called “Allogeneic transplant: The importance of a matched donor.”) The donor is often a family member, usually a brother or sister. If you do not have a good match in your family, a donor might be found from the general public through a national registry. This is sometimes called a MUD (matched unrelated donor) transplant.

Blood taken from the placenta and umbilical cord of newborns is a newer source of stem cells for allogeneic transplant. Called cord blood, this small volume of blood has a high number of stem cells that tend to multiply quickly. But the number of stem cells in a unit of cord blood is often too low for large adults, so this source of stem cells is limited to small adults and children. Doctors are now looking at different ways to use cord blood for transplant in larger adults.

An advantage of allogeneic stem cell transplant is that the donor stem cells make their own immune cells, which could help destroy any cancer cells that remain after high-dose treatment. This is called the graft-versus-cancer effect. Other possible advantages are that the donor can often be asked to donate more stem cells or even white blood cells if needed, and stem cells from healthy donors are free of cancer cells.

Still, there are many possible drawbacks to allogeneic stem cell transplants. The transplant, also known as the graft, might not take — that is, the donor cells may be more likely to die or be destroyed by the patient’s body before settling in the bone marrow. Another risk is that the immune cells from the donor can attack the patient’s body — a condition known as graft-versus-host disease (described in the section called “Problems that may come up shortly after transplant”). There is also a very small risk of certain infections from the donor cells, even though donors are tested before they donate. A higher risk comes from infections you have had, and which your immune system has under control. These infections often surface after allogeneic transplant because your immune system is held in check (suppressed) by medicines called immunosuppressive drugs. These infections can cause serious problems and even death.

Allogeneic transplant is most often used to treat certain types of leukemia, lymphomas, and other bone marrow disorders such as myelodysplasia.

Non-myeloablative or mini-transplants (allogeneic)

Some people have health conditions that would make it more risky to wipe out all of their bone marrow before a transplant. For those people, doctors can use a type of allogeneic transplant that’s sometimes called a mini-transplant. Compared with a standard allogeneic transplant, this one uses less chemo and/or radiation to get the patient ready for the transplant. Your doctor may refer to it as a non-myeloablative transplant or mention reduced-intensity conditioning (RIC). The idea here is to kill some of the cancer cells, some of the bone marrow, and suppress the immune system just enough to allow donor stem cells to settle in the bone marrow.

Unlike the standard allogeneic transplant, cells from both the donor and the patient exist together in the patient’s body for some time after a mini-transplant. But slowly, over the course of months, the donor cells take over the bone marrow and replace the patient’s own bone marrow cells. These new cells can then develop an immune response to the cancer and help kill off the patient’s cancer cells — the graft-versus-cancer effect.

One advantage of a mini-transplant is the lower doses of chemo and/or radiation. And because the stem cells aren’t all killed, blood cell counts don’t drop as low while waiting for the new stem cells to start making normal blood cells. This makes it especially useful in older patients and those with other health problems who aren’t strong enough for a standard allogeneic stem cell transplant. It may rarely be used in patients who have already had a transplant.

Mini-transplants treat some diseases better than others. They may not work well for patients with a lot of cancer in their body or those with fast-growing cancers. Also, the lowered immune response can still lead to graft-versus-host disease.

This procedure has only been used since the late 1990s and long-term patient outcomes are not yet clear. There are lower risks of complications, but the cancer may be more likely to relapse (come back). Ways to improve outcomes are still being studied.

Another future possibility is autologous transplant followed by an allogeneic mini-transplant. This is being tested in certain types of cancer, such as multiple myeloma. The autologous transplant can help decrease the amount of cancer present so that the lower doses of chemo given before the mini-transplant can work better. And the recipient still gets the benefit of the graft-versus-cancer effect of the allogeneic transplant.

Syngeneic stem cell transplant

This is a special kind of allogeneic transplant that can only be done when the recipient has an identical twin or identical triplet donor — someone who will always have the same tissue type. An advantage of syngeneic stem cell transplant is that graft-versus-host disease will not be a problem. There are no cancer cells in the transplant, either, as there would be in an autologous transplant. A disadvantage is that this type of transplant won’t help destroy any remaining cancer cells because the new immune system is so much like the recipient’s immune system. Every effort must be made to destroy all the cancer cells before the transplant is done to help keep the cancer from relapsing (coming back).

Last Medical Review: 08/23/2012
Last Revised: 10/24/2012

LINK

Wednesday, October 23, 2013

First human trial of new bone-marrow transplant method

Doctors at London's Great Ormond Street Hospital have carried out a pioneering bone-marrow transplant technique.

They say the method should help with donor shortages since it does not require a perfect cell match.

Mohammed Ahmed, who is nearly five years old, was among the first three children in the world to try out the new treatment.


He has severe combined immunodeficiency syndrome and had been waiting for a suitable donor for years.

                                                *SNIP*

"We think Mohammed is cured of his disorder. He should be able to lead a fairly normal life now."

A full report about Mohammed's therapy and the research by Great Ormond Street Hospital, King's College London and the Institute of Child Health has just been published in PLoS One journal.

There are currently about 1,600 people in the UK waiting for a bone-marrow transplant and 37,000 worldwide.

Just 30% of people will find a matching donor from within their families.

Donations involve collecting blood from a vein or aspirating bone marrow from the pelvis using a needle and syringe.

More Info Here

Thursday, September 26, 2013

Novel Drug Prevents Common Viral Disease in Stem-Cell Transplant Patients

A new drug can often prevent a common, sometimes severe viral disease in patients receiving a transplant of donated blood-making stem cells, a clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital indicates.

In a paper in the Sept. 26 issue of the New England Journal of Medicine, the researchers report that patients who took the drug CMX001 shortly after transplant were far less likely to develop cytomegalovirus (CMV) infection than were patients who took a placebo. CMV disease is a common source of illness in transplant patients and can cause pneumonia, diarrhea and digestive tract ulcers, or other problems. Although some antiviral drugs, when administered at the earliest signs of CMV infection, often forestall CMV disease, they often cause kidney dysfunction or impair patients' ability to make new blood cells.

"With current agents, between 3 and 5 percent of allogeneic [donor] transplant patients develop CMV disease within six months of transplantation, and a small number of them may die of it," says study lead author Francisco Marty, MD, of Dana-Farber and Brigham and Women's. "There clearly is a need for better treatments with fewer adverse effects. This clinical trial examined whether the disease can be prevented, rather than waiting for blood tests to show that treatment is needed."

CMV is a herpes-like virus that infects the majority of Americans by adulthood. Most often, it is held in check by the immune system and produces no symptoms. Most people are unaware they are infected, Marty explains.


In stem-cell transplant patients, however, the immune system -- based in the blood-making tissue of the bone marrow -- is replaced with donor blood-making cells after patients receive high doses of chemotherapy. During this transition period, long-dormant viruses like CMV may have an opportunity to become active. The result can be CMV disease.

Jump For More With Links Here

Monday, August 5, 2013

Race matters when a patient needs a stem cell or marrow transplant

If you become ill with a blood cancer or other disease that requires a stem cell transplant, here’s an uncomfortable fact: Your race matters. Diversity is a strength in much of life, but it’s a curse when finding a stem cell donor match.

For a successful transplant, donor and recipient must have nearly identical genes regulating certain immune cells. These genes evolved in response to the disease threats people faced long ago. “Tell me where your ancestors lived 500 years ago, and I’ll tell you who your potential donors are,” says Jeffrey Chell, an internist who leads the National Marrow Donor Program, also known as Be The Match.

African Americans have the most diverse genetics because their ancestors have been around the longest and because of intermixing with whites, Native Americans and Hispanics since Africans arrived in the Western Hemisphere. When all of humankind’s relevant genes are considered, there are 10 billion possible combinations. That means that “if your ancestors were on two or three continents,” Chell says, “it’s going to be harder to find a match.”

Genetics make the mathematics difficult for people of color. Cultural traditions, mistrust of medicine and ignorance about the need for donors make it worse.

“I didn’t know anything about bone marrow transplants until I learned that I might need one,” says Anthony Thomas, 49, a financial consultant from Ran­dalls­­town, Md., who has chronic lymphocytic leukemia. Among his African American friends and colleagues, there’s little awareness of the importance of donating, he says, although “you can bet that if Lil Wayne or Beyoncé got leukemia, that would change.”

JUMP

Wednesday, April 24, 2013

SCIENTISTS FIND SIMPLE WAY TO TRANSFORM BONE MARROW STEM CELLS INTO BRAIN CELLS…BY ACCIDENT

Scientists at the Scripps Research Institute have found a mechanism to turn bone marrow stem cells into brain cells. It is one the press release states is not only “simple” but was “serendipitous” in its discovery.


The current method for transforming marrow cells, for use in treating things like spinal cord injuries or strokes, is described as not only cumbersome but also risky. But this latest find, which was uncovered by scientists researching antibodies that activate a growth-stimulating receptor on the marrow cells, pointed to one type of antibody that causes the marrow stem cells to become a nearly mature form of brain cell.

“These results highlight the potential of antibodies as versatile manipulators of cellular functions,” Richard Lerner, the Lita Annenberg Hazen Professor of Immunochemistry at the institute and principal investigator for the new study said in a statement. “This is a far cry from the way antibodies used to be thought of—as molecules that were selected simply for binding and not function.”

In the research of one isolated antibody that activated the marrow stem cells growth receptors, researcher Jia Xie in Lerner’s laboratory said the cells started “becoming long and thin and attaching to the bottom of the dish.” Lerner speculated, and later confirmed through tests, that they were becoming neural progenitor cells.

This process of changing a one cell into a completely different type is called transdifferentiation. Lerner said in a statement that he doesn’t know of any other laboratories that have been able to use a single protein to accomplish this, as their research published in the Proceedings of the National Academy of Sciences has. Current techniques for transdifferentiation involve deprogramming cells to a state that is like that of embryonic stem cells and reprogramming them, the press release explained.


Here’s how this new method of cell transdifferentiation could be used:

In principle, according to Lerner, an antibody such as the one they have discovered could be injected directly into the bloodstream of a sick patient. From the bloodstream it would find its way to the marrow, and, for example, convert some marrow stem cells into neural progenitor cells. “Those neural progenitors would infiltrate the brain, find areas of damage and help repair them,” he said.
U.S. World News and Report stated that the team will conduct animal tests using the technique and hope to collaborate with researchers working on regenerating eye nerves.

LINK

Friday, February 8, 2013

A Comprehensive Article about Blood Cancers

           Blood Cancers: Stem Cell Transplantation Can Save a Life

Cancer can arise from any of the tissues of the human body, so the blood forming tissues (Bone marrow and Lymph glands) are no exception. Cancer that begins in the marrow is commonly called Leukemia and these cancerous cells circulate in the blood and can be easily detected by looking at the blood under a microscope. Cancer arising from the lymph glands is commonly called a Lymphoma. Another cancer arising in the bone marrow is called a Multiple myeloma but this one remains inside the bones which are often eaten up by the cancerous cells and tend to break easily. There are many subtypes of Leukemia and Lymphomas some of which are acute and aggressive; others are more indolent and run a chronic course over several years.

Cancers of the blood are commonly called Hematologic cancers as opposed to rest of the cancers which are called Solid tumors. Whereas the solid tumors constitute 90% of all cancers Blood cancers account for about 10%. This translates to about 150,000 cases of blood cancers diagnosed in the US each year. Among all human cancers, Blood cancers tend to be generally more curable, with a few exceptions. No age is exempt from developing blood cancer. In fact among the Blood cancers, Leukemia is one of the more common cancers among the pediatric age group. Fortunately children respond to cancer treatments with much better results such that childhood leukemia is cured in more than 80% of cases.

Much More Here - Symptoms, Treatments, Stem Cell/Bone Marrow Transplants

Thursday, February 7, 2013

ROBIN ROBERTS RETURNING TO 'GMA'


Robin Roberts is returning to "Good Morning America" after a 5-month leave so she could recover from her bone marrow transplant.

Robin has been battling a rare blood disorder -- myelodysplastic syndrome (MDS) -- and has been struggling with the symptoms for a year.

She recently passed the 100-day mark -- an important milestone for bone marrow transplant recipients -- and has been easing her way back into action by showing up at the GMA studio to see how her skin would react to the lights and how she would react to the stress.

Sources close to Robin told us several weeks ago ... she would not be returning until May at the earliest, but apparently her doctors felt her progress exceeded expectations.

ABC now says it's all systems go ... and, by the way, side benefit for ABC -- it's all happening smack in the middle of sweeps.

LINK